Business Model Breakdown
How Recursion Pharmaceuticals Inc Makes Money
RXRX
Market Cap
$1.9B
Annual Revenue
$36M
Profit Margin
-863.4%
Employees
800
The Short Version
Recursion Pharmaceuticals uses an advanced, integrated AI and machine learning platform, called a 'Biofoundry,' to discover and develop new drugs more efficiently and rapidly than traditional methods. They generate vast amounts of biological and chemical data, which their AI models analyze to identify potential drug candidates for various diseases. They make money through two primary avenues: collaborating with larger pharmaceutical companies (like Bayer) to accelerate their partners' drug discovery pipelines and by developing their own internal portfolio of drug candidates that they hope to bring to market or out-license, earning milestone payments and future royalties.
Where the Revenue Comes From
Partnership and collaboration revenue (from agreements like Bayer and NVIDIA)
Potential future milestone payments and royalties from internal pipeline assets
Who buys: Large pharmaceutical and biotech companies, and potentially patients if their internal drugs reach commercialization.
Why It Works (Competitive Advantages)
- ✔Proprietary AI-driven 'Biofoundry' platform for drug discovery.
- ✔Strategic partnerships with industry leaders like NVIDIA and Bayer.
- ✔Extensive dataset for AI model training and drug candidate identification.
- ✔Rapid prototyping and testing capabilities.
Economic Moat: Narrow (Intangible Assets/IP (proprietary AI/ML models, extensive biological and chemical datasets), Switching Costs (deep integration with pharma partners' R&D processes), Efficient Scale (high fixed costs of building a biofoundry, creating a barrier to entry for smaller players))
What Our Analysis Says
DVR Score as of April 27, 2026
Recursion Pharmaceuticals (RXRX) maintains significant long-term disruptive potential with its AI/ML Biofoundry and key partnerships. The recent Q4 2025 EPS beat (-$0.20 vs. -$0.30 consensus) indicates some operational efficiency gains. More importantly, positive Phase 1b/2 TUPELO data for REC-4881 (FAP) and BlackRock's increased 7.2% stake are strong positive catalysts and institutional endorsements, enhancing the company's momentum and future growth prospects. However, financial health remains a core concern with continued high cash burn and negative profitability, even if the Q1 2026 EPS estimate shows improvement. Persistent insider selling by key personnel signals a lack of conviction from some within, tempering enthusiasm. While the long-term vision is compelling, significant financial hurdles and potential future dilution keep the overall risk profile elevated, preventing a higher score despite strong strategic positioning and recent clinical progress.